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BACKGROUnD
Significant progress has been made in the treatment of selected malignancies with immune-
modulating antibodies. Phase III trials of anti-CTLA-4 in melanoma and anti-PD-1 in melanoma, 
renal cell carcinoma (RCC), and non-small cell lung cancer (NSCLC) showed improved overall 
survival (OS) compared to standard therapies (1–5). As a result, immune checkpoint inhibitors are 
now approved for the treatment of these diseases. Blockade of CTLA-4 (ipilumimab and tremeli-
mumab), PD-1 (nivolumab, pembrolizumab, pidilizumab and others), and PD-L1 [BMS 936559 
(6), durvalimumab (7), and atezolizumabes (8–11)] can produce durable responses in patients 
with metastatic cancer. Clinical trials with these agents, alone and in combination, are ongoing. 
Moreover, additional immune checkpoint modulators are in pre-clinical and clinical development. 
Other approved immunotherapies include high-dose bolus interleukin-2 (IL-2), interferon alpha-2b, 
and Sipuleucel-T. There are limited data, however, on the impact of immunotherapy in patients with 
measurable metastatic disease to the brain. Registration trials of immune therapies excluded patients 
with active brain metastases based on a historical poor prognosis in this patient population coupled 
with uncertainty about the ability of the drugs to cross the blood brain barrier (BBB). These active 
therapies might however have benefited patients with microscopic brain deposits.
Brain metastases were historically managed with whole brain radiation therapy (WBRT) or surgi-
cal resection, depending on the size, number, histology, symptoms, and location. The availability of 
high-resolution magnetic resonance imaging (MRI) and stereotactic radiosurgery (SRS) to small, 
emerging lesions has improved local lesional control. These modalities allow higher doses of radia-
tion. In many institutions, WBRT is reserved for patients with multiple or larger lesions not amenable 
to SRS (12, 13). These treatments are not without limitations and consequences. For example, WBRT 
has been associated with cognitive decline, while SRS can result in radiation necrosis, cerebral 
edema, and delayed tumor hemorrhage (14, 15). More often, however, focal therapies are limited in 
efficacy due to distant cerebral relapse and lack of treatment of microscopic tumor foci not evident 
on imaging. As new systemic treatments, particularly immune-modulating agents, show prolonged 
survival of patients with aggressive extra-cerebral disease, these drugs need to be assessed for efficacy 
in active brain metastases. There are a number of ongoing investigations to determine if these anti-
bodies cross the leaky BBB found in tumors despite their size (16, 17). Alternatively, although brain 
metastases might contain pre-existing tumor infiltrating lymphocytes (TILs), immune modulation 
induced by these agents may allow cytotoxic T cells into the tumor microenvironment in the brain, 
resulting in antitumor immunity. Several lines of evidence suggest that T cells within the tumor 
microenvironment are responsible for the responses seen with these therapies (18, 19). To date, there 
have been no published pharmacokinetic or pharmacodynamic studies in on-treatment brain tissue 
to allow determination of drug penetration into the tumor, primarily due to the difficulty accruing 
patients to trials requiring brain biopsies, particularly from patients who are responding to therapy. 
Although animal studies have been done, drug distribution and T cell activation might not reflect 
that of humans.
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Metastatic melanoma is the solid tumor with the highest 
propensity for dissemination to the brain (20). The only chemo-
therapy widely used for melanoma known to definitively cross 
BBB is temozolamide, which induced responses in 7% of mela-
noma brain metastasis patients (21). Other anti-neoplastic drugs 
that cross the BBB include fotemustine, etoposide, cisplatin, 
vinblastine, and motoxantrone and can be used depending on 
tumor cell sensitivity (22–26). Targeted therapies such as erlo-
tinib, afatinib, and lapatinib have also shown evidence of ability 
to cross the BBB (27–29).
pRECLiniCAL DATA
The ability of immune-modulating antibodies to cross the BBB 
and control brain metastases is the subject of ongoing investiga-
tions. In primary CNS tumors, preclinical data with immune-
modulating antibodies have shown promise. In mice with 
SMA-650 intracranial tumors, anti-CTLA-4 was tolerated well 
(30). An increase in CD4+ cells and decrease in T regs prolonged 
survival in these animals. Similarly, PD-1 blockade combined with 
radiation was tested in mice with GL261 intracranial tumors and 
showed improved survival (31). The combination of PD-1 and 
CTLA-4 inhibitors similarly showed improved survival in animal 
models (32). These examples suggest that BBB drug penetration 
in tumors might be obtainable, for primary CNS tumors and for 
metastatic tumors, although this remains to be verified in humans 
with each drug and tumor type.
CLiniCAL DATA
High-dose IL-2 was one of the first immune-modulating agents to 
demonstrate activity in melanoma and RCC. There have not been 
any formal trials of IL-2 specifically for patients with brain metas-
tases. A retrospective series reported a response rate in active 
brain metastases lower than expected for extra-cerebral disease, 
however without excessive toxicities (33). One of the first studies 
to investigate the effect of immunotherapy on brain metastases in 
patients with metastatic melanoma was a retrospective analysis 
of the phase II trial with ipilimumab, which reported 5 of 12 
patients were responders (34, 35). Following this observation, a 
phase II trial of ipilimumab specifically for patients with brain 
metastases from melanoma opened (36). Results of 72 patients 
accrued showed prolonged OS, particularly notable in asympto-
matic patients. These findings were confirmed in an expanded 
access protocol of ipilimumab with a 20% 1-year OS in patients 
with stable, asymptomatic brain metastases (37). Based on these 
promising results, the Italian Network for Tumor Biotherapy 
(NIBIT) designed a phase II trial of ipilimumab in combina-
tion with fotemustine (NIBIT-M1) with twenty asymptomatic 
patients with brain metastases. Stable disease or partial response 
was seen in 25% and another 25% had complete response in the 
brain (38, 39).
A follow-up randomized trial (NIBIT-M2) was subsequently 
initiated for patients with untreated melanoma brain metastases 
comparing fotemustine monotherapy, fotemustine plus ipili-
mumab 10 mg/kg and ipilimumab 3 mg/kg + nivolumab 10 mg/
kg (NCT02460068). Objectives include OS, safety, disease control 
rate (intra and extra-cerebral) objective response rate, duration 
of response, and progression-free survival. This study will also 
examine quality of life. Various groups are studying the effect 
of immune-modulating agents alone and in combination with 
other therapies for the treatment of brain metastases from mela-
noma. For example, ipilimumab and nivolumab or nivolumab 
monotherapy is being studied in a large multi-arm phase II trial 
(NCT02320058 and NCT02374242) and combinations of ipili-
mumab with various forms and schedules of radiation are being 
investigated (NCT01703507, NCT01950195 and NCT02097732). 
Results of these trials are pending.
A phase II trial of pembrolizumab for patients with metastatic 
melanoma or NSCLC and untreated brain metastases is ongo-
ing. Preliminary results from this trial were presented at ASCO 
2015 (NCT02085070) (40, 41). In this two-arm study, patients 
are eligible if they have at least 1 untreated or progressive brain 
metastasis (5–20  mm), not requiring steroids and are without 
neurological symptoms. Patients in the melanoma arm require 
brain metastasis biopsy or resection of metastatic brain lesion 
prior to starting therapy or availability of previously resected 
brain lesions for correlative studies. Patients in the NSCLC arm 
are required to have PD-L1 positive tumors. In the NSCLC 
arm, 11 patients were evaluable for response as of June 2015. 
Brain metastasis response rate was 45%, and systemic response 
rate was 45%. Only one patient with a systemic response had 
disease progression in the brain, and two patients with disease 
progression as their best systemic response were unevaluable 
in the brain due to rapid systemic progression. The duration 
of response in the brain was at least 12  weeks for four of five 
responders, and all responses were ongoing at the time of data 
analysis (40). In the melanoma arm, 18 patients were accrued at 
the time of analysis. Four patients were unevaluable due to rapid 
extra-cerebral progression or hemorrhage, and one was too early 
for response evaluation. Four patients achieved partial response, 
three had stable disease, and seven had disease progression (two 
with mixed response and one with histologically demonstrated 
pseudoprogression). Response in the body was largely concord-
ant with brain response, although in some cases brain response 
occurred after extracerebral response. Response in the brain was 
ongoing at 4+, 6+, 6+, and 11+ months (41).
Studies completed to date suggest that immune checkpoint 
inhibitors have activity in the brain that might be similar to that of 
extra-cerebral sites (42). In the phase II study of ipilimumab brain 
metastases activity in asymptomatic patients was similar to that 
of patients without brain metastases with a disease control rate 
of 24 and 27%, respectively. The 1- and 2-year progression-free 
survival were 31 and 26%, respectively (36, 43). The NIBIT-M1 
study described above confirmed these findings with an immune-
related disease control rate for patients with brain metastases 
of 50% compared with 46.5% of the entire treated population. 
Interim data from our phase II trial of pembrolizumab in patients 
with metastatic melanoma and NSCLC with untreated brain 
metastases showed that all responses in the melanoma arm were 
concordant, while three or four in the NSCLC arm were concord-
ant (40, 41). Results suggest that immune-modulating agents may 
have similar durable responses in the brain as seen systemically, 
and support use of systemic therapy alone or in combination with 
FiGURE 1 | MRi FLAiR images of two patients with perilesional while 
receiving pembrolizumab. The top and bottom frames represent the two 
separate patients. Images prior to therapy are on the left and after therapy on 
the right.
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focal therapy (SRS or surgery) in the treatment of brain metasta-
ses from immune therapy responsive diseases such as melanoma 
and lung cancer.
There are data to suggest that responses might be further 
improved by combining immune checkpoint inhibitors with 
radiation. Several studies have evaluated the combination in 
other disease sites (44–47). A number of mechanisms have been 
described explaining the combined effect; radiation upregulates 
inflammatory cytokines (i.e., TNFα, IFN-γ, and CXCL16), 
promoting tumor detection and facilitating T cell infiltration 
(48, 49). Radiation can upregulate PD-L1 (50). The abscopal 
effect, in which local radiation is thought to cause a systemic 
response resulting in shrinkage at distant sites, further supports 
the use of radiation combined with immune-modulating agents 
(51). Knisely et al. published a series of patients with metastatic 
melanoma with brain metastases who achieved a median sur-
vival of 21.3 months if they received ipilimumab and SRS versus 
4.9 months if they underwent SRS but did not receive ipilimumab 
(44). Mathew et al. looked at a similar population with 25 patients 
receiving both ipilimumab and SRS versus 33 patients receiving 
SRS alone (46). The analysis did not show a significant benefit 
in 6-month OS between the two groups, although this was not a 
randomized trial and the groups were not balanced. Lastly, Silk 
et al. reported improved OS in patients receiving ipilimumab and 
SRS (47). Exploratory analysis within the same study showed no 
increase in OS with the addition of ipilimumab to WBRT. The 
timing of administration of concurrent immune checkpoint 
inhibitors and radiation has not yet been determined. Kiess et al. 
found increased rates of progression if patients were treated with 
SRS before or during ipilimumab compared with those who 
received SRS after systemic therapy (52). Future studies will pro-
vide insight into the optimal timing for combining radiation and 
immune-modulating therapies, such as NCT02097732, which is 
investigating SRS to brain metastases before or in the middle of 
ipilimumab induction.
Toxicities unique to central nervous system metastases, such 
as vasogenic edema and tumor necrosis represent an additional 
challenge. Early recognition of potential symptoms is essential. 
One of the challenges in treating brain metastasis patients with 
immune therapy is management of neurological symptoms, 
which might be from perilesional edema, intralesional hemor-
rhage, necrosis most commonly seen in previously irradiated 
lesions, or tumor growth due to treatment failure. Examples 
of perilesional edema seen on FLAIR images before and on 
therapy in two patients receiving pembrolizumab are shown in 
Figure 1. Both patients responded well to transient steroids and 
remain on pembrolizumab with good disease control for over a 
year. Depending on the size and location of the brain metastasis, 
patients might require surgical intervention due to neurologic 
symptoms. Moreover, it is sometimes impossible to determine 
whether lesions enlarge on study due to inflammation, necrosis, 
or tumor growth, and current imaging modalities can be inad-
equate (53). Our institutional experience suggests that despite the 
indisputable benefit of systemic immune therapy in some tumor 
types, radiation necrosis occurs with greater frequency in patients 
treated with immunotherapy than other types of systemic therapy. 
We, and others, have used bevacizumab to control perilesional 
edema and worsening radiation necrosis, with variable success, 
and surgical intervention or laser interstitial thermacoagulation 
therapy is sometimes needed although caution must be taken with 
histologies more prone to hemorrhage (54–59). Furthermore, the 
incidence of seizures from perilesional edema might be decreased 
with use of prophylactic anti-epileptic medications.
FUTURE DiRECTiOnS AnD COnCLUSiOn
Use of immune therapy for non-irradiated brain metastases 
has shown promise in a small number of clinical trials, and 
requires validation in larger studies and in different tumor types. 
Experience to date suggests that activity of immune checkpoint 
inhibitors in brain metastases is similar to that of extracerebral 
metastases, and exclusion of patients with brain metastases from 
clinical investigations is no longer justified, although separate 
studies or separate cohorts for patients with untreated brain 
metastases might be required. Challenges with treating this patient 
population include drug-related toxicities such as perilesional 
edema and tumor-related confounding factors such as necrosis 
in previously irradiated lesions and intralesional hemorrhage, 
both of which might require intervention with local or systemic 
modalities such as surgery, radiation, anticonvulsants, steroids, 
or VEGF inhibitors. Efficacy of immune checkpoint inhibitors 
might be further enhanced by combining more than one inhibitor 
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or with combinations with chemotherapy, targeted therapy, or 
radiation therapy. As the breadth of immunotherapies available 
for investigation and use expands, predictive biomarkers will also 
need to be studied and validated. This can be particularly chal-
lenging in patients with brain metastases due to the morbidity 
associated with biopsy; however, if concordance of response is 
persistently observed as newer drugs are studied in this patient 
population, extra-cerebral biopsies might suffice. Clinical trials 
designed specifically for this patient population addressing the 
effects of multi-modality therapy, particularly combinations of 
immune checkpoint inhibitors and radiation, are necessary for 
improving outcomes among individuals with brain metastases.
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